CN101180261A - 用于制备盐酸西那卡塞晶型ⅰ的方法 - Google Patents

用于制备盐酸西那卡塞晶型ⅰ的方法 Download PDF

Info

Publication number
CN101180261A
CN101180261A CNA2006800179392A CN200680017939A CN101180261A CN 101180261 A CN101180261 A CN 101180261A CN A2006800179392 A CNA2006800179392 A CN A2006800179392A CN 200680017939 A CN200680017939 A CN 200680017939A CN 101180261 A CN101180261 A CN 101180261A
Authority
CN
China
Prior art keywords
cinacalcet hydrochloride
hours
solvent
cinacalcet
filtration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800179392A
Other languages
English (en)
Chinese (zh)
Inventor
R·利夫什茨-利伦
S·阿夫哈-麦丹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CN101180261A publication Critical patent/CN101180261A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/82—Purification; Separation; Stabilisation; Use of additives
    • C07C209/84—Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/82—Purification; Separation; Stabilisation; Use of additives
    • C07C209/90—Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)
  • Catalysts (AREA)
CNA2006800179392A 2005-05-23 2006-05-23 用于制备盐酸西那卡塞晶型ⅰ的方法 Pending CN101180261A (zh)

Applications Claiming Priority (33)

Application Number Priority Date Filing Date Title
US68415205P 2005-05-23 2005-05-23
US60/684,152 2005-05-23
US69698105P 2005-07-05 2005-07-05
US60,696,981 2005-07-05
US69711105P 2005-07-06 2005-07-06
US60/697,111 2005-07-06
US69861305P 2005-07-11 2005-07-11
US60/698,613 2005-07-11
US70123205P 2005-07-20 2005-07-20
US60/701,232 2005-07-20
US70291805P 2005-07-26 2005-07-26
US60/702,918 2005-07-26
US70691005P 2005-08-09 2005-08-09
US60/706,910 2005-08-09
US73005005P 2005-10-24 2005-10-24
US60/730,050 2005-10-24
US73208305P 2005-10-31 2005-10-31
US60/732,083 2005-10-31
US73300805P 2005-11-02 2005-11-02
US60/733,008 2005-11-02
US73466905P 2005-11-07 2005-11-07
US60/734,669 2005-11-07
US73512605P 2005-11-08 2005-11-08
US60/735,126 2005-11-08
US73882705P 2005-11-21 2005-11-21
US60/738,827 2005-11-21
US74178705P 2005-12-01 2005-12-01
US60/741,787 2005-12-01
US75091005P 2005-12-15 2005-12-15
US60/750,910 2005-12-15
US79480406P 2006-04-24 2006-04-24
US60/794,804 2006-04-24
PCT/US2006/020304 WO2006127933A1 (en) 2005-05-23 2006-05-23 Processes for preparing cinacalcet hydrochloride crystal form i

Publications (1)

Publication Number Publication Date
CN101180261A true CN101180261A (zh) 2008-05-14

Family

ID=37101358

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800179392A Pending CN101180261A (zh) 2005-05-23 2006-05-23 用于制备盐酸西那卡塞晶型ⅰ的方法

Country Status (12)

Country Link
US (2) US7247751B2 (https=)
EP (3) EP1975150A1 (https=)
JP (3) JP4638491B2 (https=)
KR (2) KR20070088485A (https=)
CN (1) CN101180261A (https=)
AT (1) ATE445587T1 (https=)
CA (2) CA2605736A1 (https=)
ES (1) ES2334260T3 (https=)
IL (2) IL185108A0 (https=)
MX (1) MX2007000983A (https=)
TW (1) TW200716512A (https=)
WO (2) WO2006127933A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103739500A (zh) * 2012-12-27 2014-04-23 国药一心制药有限公司 一种盐酸西那卡塞的合成与精制方法
CN104892428A (zh) * 2015-06-05 2015-09-09 南京辰逸生物科技有限公司 一种盐酸西那卡塞的制备方法
CN105439818A (zh) * 2015-12-31 2016-03-30 苏州汇和药业有限公司 一种西那卡塞中间体3-(3-三氟甲基苯基)丙醇的合成方法
CN107879939A (zh) * 2016-09-30 2018-04-06 上海天慈生物谷生物工程有限公司 一种制备 n‑((1r)‑1‑(1‑萘基)乙基)‑3‑(3‑(三氟甲基)苯基)丙‑1‑胺盐酸盐的方法

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008012061A (es) 2006-03-23 2008-12-17 Amgen Inc Metodos y composiciones para elaborar y utilizar polimorfos de cinacalcet.
WO2008000422A1 (en) * 2006-06-27 2008-01-03 Sandoz Ag Amorphous form of cinacalcet
EP1913941A1 (en) * 2006-10-19 2008-04-23 Sandoz AG Polymorphic forms and solvates of Cinacalcet hydrochloride
EP2064173A1 (en) * 2006-06-27 2009-06-03 Sandoz AG Crystalline form of cinacalcet
JP2010501642A (ja) * 2006-09-01 2010-01-21 テバ ファーマシューティカル インダストリーズ リミティド カルシウム受容体−活性化合物の固体複合材料
WO2008058236A2 (en) * 2006-11-08 2008-05-15 Dr. Reddy's Labortories, Ltd. Methods for preparing cinacalcet hydrochloride
EP1968932A1 (en) * 2006-11-20 2008-09-17 Teva Pharmaceutical Industries Ltd. Process for preparing cinacalcet
EP2170805B1 (en) * 2007-06-21 2016-03-16 Amgen Inc. Methods of synthesizing cinacalcet and salts thereof
ITMI20071261A1 (it) 2007-06-22 2008-12-23 Dipharma Francis Srl Procedimento per la preparazione di cinacalcet
US20090093652A1 (en) * 2007-08-16 2009-04-09 Michal Rafilovich Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof
AR070754A1 (es) * 2007-09-18 2010-05-05 Medichem Sa Proceso mejorado para preparar clorhidrato de cinacalcet
EP2197273B1 (en) * 2007-10-01 2014-09-24 Ascenta Therapeutics, Inc. Process for preparing r-gossypol l-phenylalaninol dienamine
US20090275780A1 (en) * 2008-05-05 2009-11-05 Medichem, S.A. Process for controlling the particle size of a 3-(trifluoromethyl)phenyl]-1-aminopropane derivative
EP2321256B1 (en) * 2008-06-18 2014-11-12 ERREGIERRE S.p.A. Process for the synthesis of cinacalcet hydrochloride
US20110178326A1 (en) * 2008-08-06 2011-07-21 Actavis Group Ptc Ehf Unsaturated cinacalcet salts and processes for preparing cinacalcet hydrochloride
US20110318417A1 (en) * 2008-12-08 2011-12-29 Actavis Group Ptc Ehf Highly pure cinacalcet or a pharmaceutically acceptable salt thereof
AU2010215520B2 (en) 2009-02-19 2016-07-21 F.I.S. - Fabbrica Italiana Sintetici S.P.A. Process for preparing Cinacalcet hydrochloride
AU2010219464A1 (en) 2009-03-05 2011-09-22 Cipla Limited Process for the preparation of cinacalcet and salts thereof, and intermediates for use in the process
WO2010128388A2 (en) 2009-05-08 2010-11-11 Aurobindo Pharma Limited An improved process for the preparation of intermediate compounds useful for the preparation of cinacalcet
CA2769659C (en) 2009-09-10 2017-10-24 Zach System S.P.A. Process for preparing cinacalcet
US8722732B2 (en) 2009-09-29 2014-05-13 Nektar Therapeutics Oligomer-calcimimetic conjugates and related compounds
IT1396623B1 (it) 2009-11-26 2012-12-14 Dipharma Francis Srl Procedimento per la preparazione di cinacalcet e suoi intermedi
CZ2011770A3 (cs) * 2011-11-25 2013-01-16 Zentiva, K.S. Zpusob výroby Cinacalcetu
CN103450027B (zh) 2012-05-29 2015-07-29 上海京新生物医药有限公司 盐酸西那卡塞的制备方法
FR2995307A1 (fr) 2012-09-07 2014-03-14 Prod Chim Auxiliaires Et De Synthese Procede de preparation du cinacalcet et de ses sels pharmaceutiquement acceptables
CN103193655B (zh) * 2013-04-15 2015-06-24 山东新华制药股份有限公司 盐酸西那卡塞晶型ⅰ的制备方法
CN104512864B (zh) * 2013-09-30 2017-08-22 中国石油化工股份有限公司 一种低温脱除微量碳氧化物的方法
MY180626A (en) 2013-11-15 2020-12-03 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
BR102015025502B1 (pt) * 2015-04-30 2022-06-21 Aegerion Pharmaceuticals, Inc Composição de lomitapida, tablete, produto de lomitapida, métodos para analisar uma composição de amostra de lomitapida e para determinar uma quantidade de uma impureza em uma amostra da composição
CN106610404B (zh) * 2015-10-21 2019-01-15 华仁药业股份有限公司 采用hplc法检测盐酸西那卡塞同分异构体的方法
KR20200022712A (ko) * 2018-08-23 2020-03-04 주식회사 오스코텍 8-브로모-2-(1-메틸피페리딘-4-일아미노)-4-(4-페녹시페닐아미노)피리도[4,3-d]피리미딘-5(6H)-온 염산염의 결정다형체 및 그 제조방법
CN109096119B (zh) * 2018-10-29 2019-10-25 江苏永安制药有限公司 一种制备盐酸西那卡塞的方法
CN110041206B (zh) * 2019-04-29 2021-10-19 梯尔希（南京）药物研发有限公司 一种西那卡塞杂质的制备方法
CN111153832B (zh) * 2020-01-20 2022-02-25 广州九植医药科技有限公司 一种西那卡塞杂质的制备方法
AU2024310586A1 (en) * 2023-06-30 2026-02-12 Chong Kun Dang Pharmaceutical Corp. New preparation method of compound and new crystalline form

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966988A (en) 1989-02-17 1990-10-30 Chevron Research Company Process for preparing acetonitrile 3-trifluoromethyl benzene
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
ES2285707T3 (es) 1994-10-21 2007-11-16 Nps Pharmaceuticals, Inc. Compuestos activos frente al receptor de calcio.
US5648541A (en) * 1995-09-28 1997-07-15 Nps Pharmaceuticals, Inc. Chiral reductions of imines leading to the syntheses of optically active amines
WO1997041090A1 (en) * 1996-05-01 1997-11-06 Nps Pharmaceuticals, Inc. Inorganic ion receptor-active compounds
GB9812413D0 (en) 1998-06-10 1998-08-05 Glaxo Group Ltd Compound and its use
PT3395338T (pt) 2003-09-12 2019-07-23 Amgen Inc Formulação de dissolução rápida de cinacalcet hcl

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103739500A (zh) * 2012-12-27 2014-04-23 国药一心制药有限公司 一种盐酸西那卡塞的合成与精制方法
CN103739500B (zh) * 2012-12-27 2016-03-23 国药一心制药有限公司 一种盐酸西那卡塞的合成与精制方法
CN104892428A (zh) * 2015-06-05 2015-09-09 南京辰逸生物科技有限公司 一种盐酸西那卡塞的制备方法
CN105439818A (zh) * 2015-12-31 2016-03-30 苏州汇和药业有限公司 一种西那卡塞中间体3-(3-三氟甲基苯基)丙醇的合成方法
CN107879939A (zh) * 2016-09-30 2018-04-06 上海天慈生物谷生物工程有限公司 一种制备 n‑((1r)‑1‑(1‑萘基)乙基)‑3‑(3‑(三氟甲基)苯基)丙‑1‑胺盐酸盐的方法

Also Published As

Publication number Publication date
WO2006127932A3 (en) 2007-02-01
US20070099998A1 (en) 2007-05-03
IL185108A0 (en) 2007-12-03
IL185494A0 (en) 2008-01-06
US20070060645A1 (en) 2007-03-15
JP2008507566A (ja) 2008-03-13
KR20070088485A (ko) 2007-08-29
WO2006127933A8 (en) 2007-08-30
US7294735B2 (en) 2007-11-13
JP2010280715A (ja) 2010-12-16
JP2008507565A (ja) 2008-03-13
WO2006127932A2 (en) 2006-11-30
EP1883618A1 (en) 2008-02-06
ATE445587T1 (de) 2009-10-15
TW200716512A (en) 2007-05-01
JP4638491B2 (ja) 2011-02-23
WO2006127933A1 (en) 2006-11-30
KR20070083471A (ko) 2007-08-24
ES2334260T3 (es) 2010-03-08
EP1975150A1 (en) 2008-10-01
US7247751B2 (en) 2007-07-24
CA2605736A1 (en) 2006-11-30
EP1883618B1 (en) 2009-10-14
CA2606099A1 (en) 2006-11-30
EP1805135A2 (en) 2007-07-11
MX2007000983A (es) 2007-04-16

Similar Documents

Publication Publication Date Title
CN101180261A (zh) 用于制备盐酸西那卡塞晶型ⅰ的方法
JP2008507566A6 (ja) シナカルセト塩酸塩結晶フォームｉの調製方法
JP2008507566A5 (https=)
CN102093360A (zh) 二氢蝶啶酮衍生物的制备方法
CN102203084A (zh) 盐酸尼洛替尼晶型
JP2008546719A (ja) 結晶形のｏ−デスメチルベンラファキシン
WO2009070314A2 (en) Crystalline form of sitagliptin
JP2008546718A (ja) 実質的に純粋なｏ−デスメチルベンラファキシン及びその調製方法。
CN104177308B (zh) 三种新型非布司他药物共晶及其制备方法
WO2009017813A1 (en) O-desmethyl venlafaxine saccharinate
JP2007520546A (ja) モンテルカストナトリウムの安定な非晶質性形態
CN101472878A (zh) O-去甲基文拉法辛晶型
CN101098850B (zh) 西布曲明的无机酸盐
CN101528698A (zh) (2s)-(4e)-n-甲基-5-[3-(5-异丙氧基吡啶)基]-4-戊烯-2-胺的盐形式
EP2217562A2 (en) Crystal forms of o-desmethylvenlafaxine fumarate
KR101501253B1 (ko) 결정성 페북소스타트 피돌레이트 염 및 이의 제조 방법
CN105237611B (zh) 积雪草酸氨丁三醇盐晶型及其制备方法
EP2064173A1 (en) Crystalline form of cinacalcet
CN101098849A (zh) 西布曲明的磺酸盐
CN110914246A (zh) 3-(3,5-二氯-4-羟基苯甲酰)-1,1-二氧代-2,3-二氢-1,3-苯并噻唑的晶型及其盐
CN110606826B (zh) 托拉塞米钠一水合物、其晶型及组合物
JP4005731B2 (ja) アミノエチルフェノキシ酢酸誘導体の結晶多形
CN114845993A (zh) 1-(4-苄氧基-苄基)-3-甲基-硫脲的多晶型物
WO2022194160A1 (zh) 非索替尼固体形式及其制备方法
US20080076826A1 (en) Polymorphic crystal of 4'-{2-[ (1s, 2r) - 2- hydroxy -2- (4-hydroxyphenyl) -1- methylethylamino] ethoxy} - 3 - isopropyl-3', 5' -dimethylbiphenyl - 4 - carboxylic acid hydrochloride

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080514